CR20200610A - Nuevos derivados de isoxazolit éter como pan de gaba a alfa 5 - Google Patents
Nuevos derivados de isoxazolit éter como pan de gaba a alfa 5Info
- Publication number
- CR20200610A CR20200610A CR20200610A CR20200610A CR20200610A CR 20200610 A CR20200610 A CR 20200610A CR 20200610 A CR20200610 A CR 20200610A CR 20200610 A CR20200610 A CR 20200610A CR 20200610 A CR20200610 A CR 20200610A
- Authority
- CR
- Costa Rica
- Prior art keywords
- alpha5
- gaba
- pam
- sup
- ether derivatives
- Prior art date
Links
- LRJJZSXDNXHKQV-UHFFFAOYSA-N 3-(1,2-oxazol-3-yloxy)-1,2-oxazole Chemical class C1=CON=C1OC=1C=CON=1 LRJJZSXDNXHKQV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
<p>La invención proporciona nuevos compuestos que tienen la Fórmula general (I) o (II) en donde R<sup>2</sup>, R<sup>3</sup>, R<sup>5</sup>, R<sup>99</sup>, W, Y y Z son como se describen en la presente descripción, composiciones que incluyen los compuestos y métodos de uso de los compuestos.</p>
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18177522 | 2018-06-13 | ||
EP18177825 | 2018-06-14 | ||
PCT/EP2019/065129 WO2019238633A1 (en) | 2018-06-13 | 2019-06-11 | New isoxazolyl ether derivatives as gaba a alpha5 pam |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20200610A true CR20200610A (es) | 2021-02-05 |
Family
ID=66776367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20200610A CR20200610A (es) | 2018-06-13 | 2019-06-11 | Nuevos derivados de isoxazolit éter como pan de gaba a alfa 5 |
Country Status (18)
Country | Link |
---|---|
US (1) | US11840528B2 (es) |
EP (1) | EP3807269A1 (es) |
JP (1) | JP7478676B2 (es) |
KR (1) | KR20210021019A (es) |
CN (1) | CN112424196A (es) |
AU (1) | AU2019286312B2 (es) |
BR (1) | BR112020025355A2 (es) |
CA (1) | CA3102101A1 (es) |
CL (1) | CL2020003214A1 (es) |
CR (1) | CR20200610A (es) |
IL (1) | IL279266B2 (es) |
MA (1) | MA52868A (es) |
MX (1) | MX2020013518A (es) |
PE (1) | PE20210555A1 (es) |
PH (1) | PH12020500674A1 (es) |
SG (1) | SG11202012200QA (es) |
TW (1) | TWI816812B (es) |
WO (1) | WO2019238633A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202202495A (zh) | 2020-03-26 | 2022-01-16 | 匈牙利商羅特格登公司 | 作為gamma-胺基丁酸A受體次單元alpha 5受體調節劑之㖠啶及吡啶并〔3,4-c〕嗒𠯤衍生物 |
HUP2100338A1 (hu) | 2021-09-29 | 2023-04-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2682301A1 (en) * | 2007-04-18 | 2008-10-30 | Astrazeneca Ab | Xanthine compounds having a positive allosteric gabab receptor modulator effect |
PT2767536E (pt) | 2007-12-04 | 2015-11-17 | Hoffmann La Roche | Derivados de isoxazolo-piridina |
US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
JP5774982B2 (ja) | 2008-05-19 | 2015-09-09 | サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. | イミダゾ[1,2−a]ピリジン化合物 |
SG175333A1 (en) | 2009-05-05 | 2011-12-29 | Hoffmann La Roche | Isoxazole-pyrazole derivatives |
US8604062B2 (en) | 2011-10-20 | 2013-12-10 | Hoffman-La Roche Inc. | Process for the preparation of isoxazolyl-methoxy nicotinic acids |
US8785435B2 (en) | 2011-10-20 | 2014-07-22 | Hoffmann-La Roche Inc. | Solid forms |
MX2019006696A (es) | 2016-12-08 | 2019-08-21 | Hoffmann La Roche | Nuevos derivados de isoxazolil eter como moduladores alostericos positivos (pam) de acido gamma-aminobutirico (gaba) a alfa5. |
-
2019
- 2019-06-11 AU AU2019286312A patent/AU2019286312B2/en active Active
- 2019-06-11 CA CA3102101A patent/CA3102101A1/en active Pending
- 2019-06-11 JP JP2020569188A patent/JP7478676B2/ja active Active
- 2019-06-11 CR CR20200610A patent/CR20200610A/es unknown
- 2019-06-11 MX MX2020013518A patent/MX2020013518A/es unknown
- 2019-06-11 EP EP19729015.8A patent/EP3807269A1/en active Pending
- 2019-06-11 MA MA052868A patent/MA52868A/fr unknown
- 2019-06-11 KR KR1020217000958A patent/KR20210021019A/ko not_active Application Discontinuation
- 2019-06-11 BR BR112020025355-3A patent/BR112020025355A2/pt unknown
- 2019-06-11 CN CN201980046146.0A patent/CN112424196A/zh active Pending
- 2019-06-11 WO PCT/EP2019/065129 patent/WO2019238633A1/en active Application Filing
- 2019-06-11 IL IL279266A patent/IL279266B2/en unknown
- 2019-06-11 SG SG11202012200QA patent/SG11202012200QA/en unknown
- 2019-06-11 PE PE2020001963A patent/PE20210555A1/es unknown
- 2019-06-12 TW TW108120285A patent/TWI816812B/zh active
-
2020
- 2020-12-10 PH PH12020500674A patent/PH12020500674A1/en unknown
- 2020-12-10 CL CL2020003214A patent/CL2020003214A1/es unknown
- 2020-12-11 US US17/119,977 patent/US11840528B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2021527099A (ja) | 2021-10-11 |
EP3807269A1 (en) | 2021-04-21 |
US20210094945A1 (en) | 2021-04-01 |
AU2019286312B2 (en) | 2023-08-17 |
CA3102101A1 (en) | 2019-12-19 |
BR112020025355A2 (pt) | 2021-03-09 |
CN112424196A (zh) | 2021-02-26 |
MA52868A (fr) | 2021-04-21 |
US11840528B2 (en) | 2023-12-12 |
TWI816812B (zh) | 2023-10-01 |
AU2019286312A1 (en) | 2021-01-07 |
CL2020003214A1 (es) | 2021-05-07 |
IL279266B1 (en) | 2023-11-01 |
KR20210021019A (ko) | 2021-02-24 |
MX2020013518A (es) | 2021-02-26 |
PE20210555A1 (es) | 2021-03-17 |
IL279266B2 (en) | 2024-03-01 |
WO2019238633A1 (en) | 2019-12-19 |
IL279266A (en) | 2021-01-31 |
PH12020500674A1 (en) | 2021-06-07 |
SG11202012200QA (en) | 2021-01-28 |
TW202016106A (zh) | 2020-05-01 |
JP7478676B2 (ja) | 2024-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021005714A (es) | Nuevos compuestos heterociclicos. | |
MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
MX2021014443A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
PH12021500014A1 (en) | Fused ring compounds | |
MX2021001433A (es) | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa. | |
PH12019500664A1 (en) | New isoxazolyl ether derivatives as gaba a alpha5 pam | |
CR20200416A (es) | Nuevos compuestos heterocíclicos | |
PH12020500655A1 (en) | Compounds | |
MX2023005160A (es) | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma. | |
MX2020009234A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos. | |
CR20220116A (es) | Compuestos heterocíclicos | |
CR20220004A (es) | Nuevos compuestos heterocíclicos | |
ZA202309446B (en) | Rapamycin analogs and uses thereof | |
CR20220117A (es) | Compuestos heterocíclicos | |
MX2021003843A (es) | Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer. | |
MX2021003427A (es) | Nuevos oxadiazoles. | |
MX2020012760A (es) | Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2. | |
ZA202101487B (en) | Novel compounds | |
CR20220478A (es) | Derivados de benzodiazepinas como pam de gaba a gamma 1 | |
PH12020500674A1 (en) | New isoxazolyl ether derivatives as gaba a alpha5 pam | |
MX2021001904A (es) | Formas solidas de benzoxaborol sustituido y composiciones de las mismas. | |
MX2023008634A (es) | Análogos de rapamicina y usos de estos. | |
WO2018166993A3 (en) | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | |
MX2021015889A (es) | Nuevos inhibidores de egfr. | |
MX2021003430A (es) | Nuevos oxadiazoles. |